International Journal of Hematology最新文献_第6页

Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms. 神经肽TIP39诱导PTH2受体阳性髓系肿瘤自噬。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-04-27 DOI: 10.1007/s12185-025-03985-3

Kento Ono, Hiroto Horiguchi, Satoshi Iyama, Ken Sato, Saori Ibuki-Shimoyama, Shotaro Shirato, Yusuke Sugama, Akari Goto, Masayoshi Kobune

{"title":"Neuropeptide TIP39 induces autophagy in PTH2 receptor-positive myeloid neoplasms.","authors":"Kento Ono, Hiroto Horiguchi, Satoshi Iyama, Ken Sato, Saori Ibuki-Shimoyama, Shotaro Shirato, Yusuke Sugama, Akari Goto, Masayoshi Kobune","doi":"10.1007/s12185-025-03985-3","DOIUrl":"10.1007/s12185-025-03985-3","url":null,"abstract":"Neuropeptides are chemical messengers that are synthesized and released by nerve cells. Studies suggest that neuropeptides released from the nervous system in bone marrow may be involved in the regulation of hematopoiesis and survival of leukemic stem cells (LSC). Parathyroid hormone 2 receptor (PTH2R), a new LSC marker, is expressed on CD34 + leukemic cells. Its ligand, tuberoinfundibular peptide of 39 residues (TIP39), is expressed in the nervous system. However, the role of the TIP39-PTH2R axis in leukemic cells is unclear. We investigated the function of this axis in leukemic cell lines, as well as primary CD34 + myelodysplastic syndrome (MDS) and AML cells. Expression of PTH2R mRNA was higher in primary CD34 + MDS (GSE58831) or CD34 + CD38-AML (GSE24395) cells than in healthy volunteers. TIP39 reduced apoptosis in the leukemic cell lines Kasumi-1 and SKM-1. LC3-II expression was increased after incubation with TIP39, and was augmented in leukemic cell lines treated with lysosome inhibitors. This suggests that TIP39 could induce autophagy. Analysis of a public database (GSE58831) showed that high PTH2R expression was associated with poor overall survival and was an independent prognostic factor in MDS/AML patients. Our results suggest that the TIP39-PTH2R axis is a potential therapeutic target.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"400-412"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inborn errors of immunity-associated gene variants in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. eb病毒相关的噬血细胞淋巴组织细胞病中免疫相关基因变异的先天错误

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-06-25 DOI: 10.1007/s12185-025-04028-7

Kenichi Sakamoto, Shutaro Inoue, Aiko Sato-Otsubo, Kenichi Chiba, Ai Okada, Yuichi Shiraishi, Motohiro Kato, Ryu Yanagisawa, Yozo Nakazawa

引用次数: 0

Use of activated partial thrombin time and prothrombin time for quality assessment of fresh frozen plasma. 利用活化部分凝血酶时间和凝血酶原时间评价新鲜冷冻血浆的质量。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-04-12 DOI: 10.1007/s12185-025-03984-4

Yao Layibo, Essohana Padaro, Hèzouwè Magnang, Magnime Badassan, Irenée M D Kuéviakoé, Koffi Mawussi, Lochina Fétéké

{"title":"Use of activated partial thrombin time and prothrombin time for quality assessment of fresh frozen plasma.","authors":"Yao Layibo, Essohana Padaro, Hèzouwè Magnang, Magnime Badassan, Irenée M D Kuéviakoé, Koffi Mawussi, Lochina Fétéké","doi":"10.1007/s12185-025-03984-4","DOIUrl":"10.1007/s12185-025-03984-4","url":null,"abstract":"The aim of this study was to evaluate the usefulness of activated partial thromboplastin time (APTT) and prothrombin time (PT) for determining the quality of fresh frozen plasma (FFP) units in low-income countries. Quality control was conducted for 66 randomly selected FFP units after 3 months of freezing at - 20 °C. The average volume of the FFP units was 177.8 ± 17.3 mL, with average concentrations of 79.9 ± 40.2 IU/dL for factor VIII, 83.4 ± 29.3 IU/dL for factor IX, and 2.3 ± 0.7 g/L for fibrinogen. Fifty-six percent of the FFP units had a factor VIII level greater than or equal to 70 IU/dL. Unlike PT, the PT ratio, and the international normalized ratio, both APTT and the APTT ratio provided useful information regarding factor VIII level compliance, with areas under the curve of 71% and 73%, respectively. The optimal cutoff values for FFP unit compliance assessment were 40 s for APTT and 1.23 for the APTT ratio. Accuracy rates were 65% and 70%, with Cohen's kappa coefficients of 0.31 and 0.40 for the APTT and APTT ratios, respectively. APTT outperformed PT, and showed fair to moderate agreement with factor VIII level compliance in FFP units.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"392-399"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent progress in clonal hematopoiesis: expanding the concept. 克隆造血的最新进展：概念的拓展。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-07-31 DOI: 10.1007/s12185-025-04034-9

Shigeru Chiba

引用次数: 0

Multiple myeloma presenting with retroperitoneal fibrosis and elevated IgG4. 多发性骨髓瘤表现为腹膜后纤维化和IgG4升高。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-05-11 DOI: 10.1007/s12185-025-03999-x

Kensuke Kayamori, Katsuhiro Shono, Masahiro Onoda, Akira Yokota

引用次数: 0

ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights. ASXL1突变相关克隆造血和年龄相关疾病：临床证据和分子见解

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-09-01 Epub Date: 2025-08-07 DOI: 10.1007/s12185-025-04038-5

Naru Sato, Susumu Goyama, Toshio Kitamura

{"title":"ASXL1 mutation-related clonal hematopoiesis and age-related diseases: clinical evidence and molecular insights.","authors":"Naru Sato, Susumu Goyama, Toshio Kitamura","doi":"10.1007/s12185-025-04038-5","DOIUrl":"10.1007/s12185-025-04038-5","url":null,"abstract":"Clonal hematopoiesis (CH) is defined as the age-associated expansion of hematopoietic stem and progenitor cells harboring somatic mutations, most frequently in epigenetic regulators such as DNMT3A, TET2, and ASXL1. Although CH was initially recognized as a precursor to hematological malignancies, accumulating evidence has led to its broad recognition as a relevant factor in various age-related nonmalignant diseases, particularly those with inflammatory components, such as cardiovascular disease, autoimmune disorders, and solid tumors. Notably, the increased overall mortality associated with CH is primarily driven by cardiovascular complications rather than hematological malignancies. Among CH-associated genes, ASXL1 mutations are distinguished by their strong associations with adverse clinical outcomes and pro-inflammatory signatures. However, compared to TET2 and DNMT3A, the molecular and pathological implications of ASXL1-mutated CH remain underexplored. Recent studies have expanded the disease spectrum of ASXL1 mutations beyond hematological malignancies, implicating them in clonal expansion and systemic inflammation. This review aims to summarize the current epidemiological and experimental insights into ASXL1-mutated CH, focusing on its potential contributions to inflammation-associated diseases. By integrating clinical observations and emerging mechanistic data, we highlight the urgent need for deeper investigation into ASXL1-driven CH and its systemic consequences beyond hematological transformation.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"327-340"},"PeriodicalIF":1.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fecal microbiota transplantation for Crohn's disease-like intestinal lesions arising after allogeneic stem cell transplantation. 粪便微生物群移植治疗同种异体干细胞移植后出现的克罗恩病样肠道病变。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-28 DOI: 10.1007/s12185-025-04049-2

Shinsuke Kusakabe, Ryumei Kurashige, Kentaro Fukushima, Kentaro Shimizu, Takeo Yoshihara, Daisuke Motooka, Shota Nakamura, Masako Kurashige, Keiichi Nakata, Akihisa Hino, Hidenori Kasahara, Tomoaki Ueda, Jiro Fujita, Naoki Hosen, Tetsuo Takehara, Jun Oda

{"title":"Fecal microbiota transplantation for Crohn's disease-like intestinal lesions arising after allogeneic stem cell transplantation.","authors":"Shinsuke Kusakabe, Ryumei Kurashige, Kentaro Fukushima, Kentaro Shimizu, Takeo Yoshihara, Daisuke Motooka, Shota Nakamura, Masako Kurashige, Keiichi Nakata, Akihisa Hino, Hidenori Kasahara, Tomoaki Ueda, Jiro Fujita, Naoki Hosen, Tetsuo Takehara, Jun Oda","doi":"10.1007/s12185-025-04049-2","DOIUrl":"https://doi.org/10.1007/s12185-025-04049-2","url":null,"abstract":"Several cases of inflammatory bowel disease (or similar gastrointestinal lesions) arising after allogeneic hematopoietic stem cell transplantation have been reported, but the effect of intestinal dysbiosis on development of these lesions remains unclear. We performed fecal microbiota transplantation (FMT) and 16S rRNA microbiome analysis in a patient who developed Crohn's disease-like lesions after allogeneic transplantation. A 62-year-old woman underwent haploidentical stem cell transplantation from her daughter to treat double-hit lymphoma relapsed after chimeric antigen receptor T-cell therapy, and achieved remission without developing acute graft-versus-host disease. Eight months later, she developed Crohn's disease-like intestinal lesions after cytomegalovirus enteritis. Her condition did not improve with the conventional treatment, so she underwent FMT from her daughter as part of a clinical trial. Diarrhea gradually improved, and follow-up endoscopy 4 months after the FMT showed ulcer healing and scarring. The 16S rRNA analysis revealed a reduction in the relative abundance of the Enterococcus genus after FMT, suggesting that dysbiosis may have contributed to lesion development. The patient is currently on a regular diet, with no symptom recurrence, and the primary disease remains in remission. Although this outcome suggests that FMT is effective, careful patient selection is required to reduce the risk of FMT-associated sepsis.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data. 达沙替尼在成人Ph + ALL中优于伊马替尼：汇集JALSG试验数据的倾向评分匹配分析。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-27 DOI: 10.1007/s12185-025-04058-1

Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Itaru Matsumura, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Yasushi Miyazaki, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Hitoshi Kiyoi

{"title":"Dasatinib is superior to imatinib in adult Ph + ALL: a propensity score-matched analysis of pooled JALSG trial data.","authors":"Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Itaru Matsumura, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Yasushi Miyazaki, Emiko Sakaida, Yoshinobu Maeda, Takahiro Yamauchi, Hitoshi Kiyoi","doi":"10.1007/s12185-025-04058-1","DOIUrl":"https://doi.org/10.1007/s12185-025-04058-1","url":null,"abstract":"This study compared dasatinib and imatinib in adult Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). Using pooled data from three JALSG prospective trials (Ph + ALL202, Ph + ALL208, Ph + ALL213), we analyzed outcomes for 206 patients aged 15-64 years treated with dasatinib (n = 74) or imatinib (n = 132) in combination with chemotherapy. We applied propensity score matching (1:1) and inverse probability of treatment weighting to minimize selection bias and balance baseline characteristics. Dasatinib plus chemotherapy was associated with significantly higher complete molecular response rates after induction therapy compared with imatinib. In the propensity score-matched cohort (n = 68 patients per group), 3-year event-free survival (EFS) was significantly higher with dasatinib (73 vs. 49%, P = 0.01), as was 3-year overall survival (OS) (85 vs. 60%, P = 0.004). Multivariate analysis, incorporating allogeneic stem cell transplantation in first complete remission as a covariate, confirmed that dasatinib had an independent favorable prognostic impact on EFS (hazard ratio [HR], 0.54; P = 0.02) and OS (HR, 0.39; P = 0.003). Although the 3-year cumulative incidence of relapse tended to be lower with dasatinib (18 vs. 40%, P = 0.07), non-relapse mortality was comparable between groups (8.8 vs. 12%, P = 0.33). This analysis demonstrates improved survival with dasatinib-based therapy in adult Ph + ALL, informing tyrosine kinase inhibitor selection in treatment planning.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk. 采用高剂量甲氨蝶呤和鞘内化疗预防中枢神经系统可提高中枢神经系统复发风险高的DLBCL患者的生存率。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-27 DOI: 10.1007/s12185-025-04055-4

Yuri Miyazawa, Akihiko Yokohama, Takuma Ishizaki, Takayuki Saitoh, Akio Saito, Kohtaro Toyama, Takeki Mitsui, Kayoko Murayama, Hidemi Ogura, Norifumi Tsukamoto, Hiroshi Handa

{"title":"CNS prophylaxis with high-dose methotrexate and intrathecal chemotherapy improves survival in DLBCL with high CNS relapse risk.","authors":"Yuri Miyazawa, Akihiko Yokohama, Takuma Ishizaki, Takayuki Saitoh, Akio Saito, Kohtaro Toyama, Takeki Mitsui, Kayoko Murayama, Hidemi Ogura, Norifumi Tsukamoto, Hiroshi Handa","doi":"10.1007/s12185-025-04055-4","DOIUrl":"https://doi.org/10.1007/s12185-025-04055-4","url":null,"abstract":"Objective: Central nervous system (CNS) prophylaxis is recommended for patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk of CNS relapse. This study aimed to determine the impact of CNS prophylaxis on CNS relapse rates and overall survival (OS) in this patient population, as well as the optimal method for CNS prophylaxis.Methods: This was a retrospective analysis of 178 patients with DLBCL at high risk of CNS relapse who were treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) or its derivatives with (N = 60) or without (N = 118) CNS prophylaxis.Results: The 2-year CNS relapse rate was 17.6% in the all-prophylaxis group (HD-MTX 17.4%, IT 48.1%, and HD-MTX + IT 6.2%) and 13.0% in the non-prophylaxis group, with no significant difference between groups. However, HD-MTX + IT decreased the risk of CNS relapse. After a median follow-up of 72.8 months, HD-MTX + IT addition significantly improved the 5-year OS (HD-MTX 73.5%, IT 44.4%, HD-MTX + IT 93.2%; non-prophylaxis group 58.0%; p = 0.013). This advantage was maintained in the multivariate analysis (hazard ratio: 0.160; 95% confidence interval: 0.039-0.663; p = 0.012).Conclusions: CNS prophylaxis with HD-MTX + IT improved the prognosis of patients with DLBCL at high risk of CNS relapse.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144953265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of alternate day versus daily oral iron therapy in children with iron deficiency anemia: a randomized controlled trial. 缺铁性贫血儿童隔日口服铁治疗与每日口服铁治疗的疗效：一项随机对照试验

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-17 DOI: 10.1007/s12185-025-04048-3

Pranati Grover, Abhilasha S

{"title":"Efficacy of alternate day versus daily oral iron therapy in children with iron deficiency anemia: a randomized controlled trial.","authors":"Pranati Grover, Abhilasha S","doi":"10.1007/s12185-025-04048-3","DOIUrl":"https://doi.org/10.1007/s12185-025-04048-3","url":null,"abstract":"Background: Iron deficiency anemia (IDA) is the leading cause of nutritional anemia. In some cases, oral iron therapy (OIT) fails to achieve an optimal therapeutic response. Oral doses of iron acutely increase serum hepcidin, resulting in decreased iron absorption and poor response treatment.Objective: The primary objective was to assess the efficacy of alternate-day versus twice-daily OIT in children with IDA. The secondary objective was to study the effects of alternate versus twice-daily OIT on serum hepcidin levels and to compare gastrointestinal side effects between groups.Methods: This was an RCT of 40 IDA patients, aged 6 months 10 years. The first group received twice-daily OIT, and the second group received alternate-day OIT. Serum hepcidin levels were measured at baseline and 48 h after starting OIT. Changes in hemoglobin level were noted after 30 days.Results: Patients who received alternate-day OIT had increase hemoglobin (P = 0.002) and decrease serum hepcidin (P = 0.01). Four of twenty in the alternate-day group (20%) had gastrointestinal side effects (P = 0.01).Conclusion: Children who received alternate-day OIT had lower serum hepcidin levels, which resulted in better iron absorption and compliance, significant improvement in hemoglobin levels, and fewer gastrointestinal side effects.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0